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Abstract (181 words) 
Type 2 diabetes and cardiovascular disease are complex disorders involving metabolic and 
inflammatory mechanisms. Here we investigated whether sCD93, a group XIV c-type lectin 
of the endosialin family, plays a role in metabolic dysregulation or carotid intima-media 
thickness (IMT). Whilst no association was observed between sCD93 and IMT, sCD93 levels 
were significantly lower in subjects with type 2 diabetes (n=901, mean±sd: 
156.6±40.0ng/mL)) compared to those without (n=2470, 164.1±44.8ng/mL, p<0.0001 
Genetic variants associated with diabetes risk (DIAGRAM consortium) did not influence 
sCD93 levels (individually or combined in a SNP score). In a prospective cohort, lower 
sCD93 levels preceded diabetes development. Consistent with this, a cd93-deficient mouse 
model (in addition to apoe deficiency) demonstrated no difference in atherosclerotic lesion 
development compared to apoe-/- cd93-sufficient littermates. However, cd93-deficient mice 
showed impaired glucose clearance and insulin sensitivity (compared to littermate controls) 
after a high fat diet. Expression of cd93 was observed in pancreatic islets, and leaky vessels 
were apparent in cd93-deficient pancreases. We further demonstrated that stress-induced 
release of sCD93 is impaired by hyper-glycaemia. Therefore, we propose CD93 as an 
important component in glucometabolic regulation.  
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Introduction 
Subjects with type 2 diabetes have 2 to 4-fold greater risk for developing cardiovascular 
disease (CVD) than those without. Preventative strategies targeting CVD have shown little 
progress in subjects with type 2 diabetes, despite their efficacy in subjects without diabetes. 
Although complete understanding of mechanisms leading to CVD is lacking, a combination 
of metabolic dysregulation and inflammatory pathways are important contributors. Therefore, 
elucidation of pathways linking metabolic dysregulation and inflammation could pinpoint 
potential therapeutic targets for reducing CVD, especially in subjects with type 2 diabetes.  
CD93 is a group XIV c-type lectin belonging to the endosialin family, originally described as 
a component of the complement system (1). CD93 is composed of a cytoplasmic tail 
containing a PDZ binding domain (2), a transmembrane domain containing metalloproteinase 
sites, an extracellular region containing a mucin-like domain that is highly glycosylated, 5 
EGF domains (4 in mice) and a unique C-type lectin domain. CD93 is predominantly 
expressed on endothelial cells, but also in innate immune cells such as neutrophils and 
monocytes as well as in megakaryocytes (3). In response to certain inflammatory molecules, 
the transmembrane CD93 is cleaved and the extracellular segment is released into the 
circulation as soluble CD93 (sCD93) (4; 5). It is still unknown whether the released sCD93 
has a distinct function, or whether release of this fragment is merely to enable the intra-
cellular remnant to respond to the cellular stress. Described as a factor involved in removal of 
apoptotic bodies, CD93 has also been involved in B cell maturation and Natural Killer T cell 
(iNKT cell) survival (6). EGF domains are believed to be involved in angiogenesis (7) and the 
moesin-binding domain (8) is required for endothelial cell-cell interactions (9). 
Regarding metabolism and CVD, CD93 is a plausible candidate in the mouse non-obese 
diabetes Idd13 locus (10), and we have previously shown that reduced levels of circulating 
sCD93 are associated with increased risk of myocardial infarction (MI) (11). More recently, 
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the CD93 gene has been identified as a potential regulator of pathways common to both type 
2 diabetes and CVD (12). Interestingly, CD93 expression is up-regulated by conditions 
relevant to diabetes or its complications, for example flow-related shear stress (13) due to 
endothelial dysfunction; during the development of new but leaky blood vessels (14) as 
observed in retinopathy; during ischemia-related inflammation of cerebral vascular 
endothelium (15) thus reflecting MI. 
Here we investigated sCD93 for effects on markers of metabolic dysregulation and early 
cardiovascular disease in human cohorts and in a mouse model with a genetic deficiency in 
sCD93. We further examined the mechanisms by which sCD93 acts.  
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Research Design and Methods 
Discovery analyses: IMPROVE 
The IMPROVE cohort has previously been described (16; 17). Briefly, subjects with at least 3 
established CVD risk factors without symptoms or history of coronary artery disease were 
enrolled from 7 European centres (at latitudes ranging from 43 to 62° North). Medical history, 
anthropometric measurements and blood samples were obtained at baseline and standard 
biochemical phenotyping was performed. Blood samples were stored at -80⁰C. Extensive 
carotid intima-media thickness (IMT) phenotyping was performed by ultrasound at baseline, 
as well as 15 and 30 months after enrolment (16; 17).  Approval was granted by the regional 
ethics committee for each recruitment centre and written informed consent was provided by 
all participants. Type 2 diabetes was defined as diagnosis, anti-diabetic medication or fasting 
glucose ≥7mmol/L. Soluble CD93 was measured using the Mesoscale platform, using the 
previously validated ELISA antibodies (11) and SECTOR Imager 2400. Characteristics of the 
cohort are presented in Table 1. 
IMPROVE Genotyping 
Reported type 2 diabetes risk-associated SNPs (18) were genotyped in the IMPROVE cohort 
using the Illumina Metabochip (19) and Immunochip (20) platforms. Genotyping was 
conducted at the SNP&SEQ Technology Platform, Uppsala University, Sweden and standard 
quality control was conducted; Subject exclusions: low call rate (<95%), cryptic relatedness 
or ambiguous sex. SNPs exclusions; failing call rate (<95%) or Hardy–Weinberg equilibrium 
(p<5*10-6) thresholds. After quality control, multi-dimensional scaling (MDS) components 
were calculated using PLINK (21) with default settings. The first MDS component 
demonstrates strong correlations with latitude of recruitment centre (Spearmans rank Rho 
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0.935 p<0.0001 and Rho 0.946 p<0.0001 for subjects without and with type 2 diabetes 
respectively).  
Statistical analyses: IMPROVE Epidemiology 
The trend test for ordered groups was used to assess an effect of recruitment centre latitude. 
Differences in sCD93 levels between men/women and subjects with/without diabetes were 
assessed by T-test. Associations between sCD93 levels and established risk factors were 
assessed by Spearman rank correlation coefficients. Skewed variables, including sCD93, were 
log transformed for further statistical analyses. Multivariable regression analysis was used to 
identify markers of metabolism or CVD with significant effects on sCD93 levels. Variables 
considered for inclusion were: age and sex (forced into the models), height, weight, BMI, 
waist to hip ratio (WHR), systolic and diastolic blood pressure (SBP and DBP respectively), 
LDL cholesterol, HDL cholesterol, triglycerides (TGs), fasting glucose, C-reactive protein 
(CRP), proinsulin, insulin, HOMA indices, adiponectin, leptin, interleukin 5 (IL-5), current 
smoking, lipid-lowering and anti-hypertensive medication. Multivariable regression, adjusted 
for established CVD risk markers (age, gender, mds1-3, BMI, SBP, HDL, TGs and current 
smoking) (22), was used to assess the effect of sCD93 levels on measures of IMT. Analyses 
were conducted using STATA 11.2 (STATCorp, College Station, TX, USA). 
Statistical analyses: Genetics 
Linear regression analyses assuming an additive genetic model were conducted in PLINK 
(21) to assess the influence of type 2 diabetes risk-associated SNPs on sCD93 levels, 
adjusting for age, sex and population structure (MDS1-3). Genotypes of 52 (of 62 known 
(18)) type 2 diabetes-risk associated SNPs were combined in an unweighted SNP score by 
summing the reported (18) type 2 diabetes risk-increasing alleles for each subject (thus 
representing the total burden of genetically determined type 2 diabetes risk). Only subjects 
without type 2 diabetes and with complete genotyping were included in this analysis. The 
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score was tested for influence on levels of sCD93, using a linear regression model as above, 
in STATA 11.2 (STATCorp,Texas, USA).  
Replication analyses: Stockholm Diabetes Prevention Program (SDPP) 
The SDPP is a prospective study of subjects from the Stockholm area, aged 35-55 years at 
baseline (23). Briefly, blood samples, oral glucose tolerance tests (OGTT), basic clinical 
phenotyping and questionnaires were conducted on participants at baseline and after 8-10 
years of follow-up. Levels of sCD93 were measured by Mesoscale in baseline samples and in 
a subset of follow-up samples (Online Supplemental Figure 1). Baseline samples were from 
subjects newly diagnosed with normal glucose tolerance (NGT, n=843), pre-diabetes (defined 
as impaired glucose tolerance and/or impaired fasting glucose, n=326) and type 2 diabetes 
(n=113). Follow-up samples from NGT subjects at baseline were also analysed. Some 
subjects remained NGT (n=370), whilst others had progressed to pre-diabetes (n=314) or type 
2 diabetes (158). Karolinska Institutets Ethics committee approved the study and all subject 
gave their informed consent. ANOVA (adjusted for age and sex) was used to compare levels 
of sCD93 between glucose tolerance groups at baseline or after follow-up. T-tests were used 
to compare baseline levels of sCD93 from subjects diagnosed as NGT and prediabetes or T2D 
at follow-up. The effect of baseline sCD93 levels on risk of developing prediabetes or T2D 
was assessed using logistic regression, adjusting for age and sex, or age, sex, current smoking, 
BMI and blood pressure medication. Analyses were conducted in STATA 11.2 
(STATCorp,Texas, USA). 
Cd93-deficient mice 
The cd93-deficient mouse was generated by the trans-NIH Knock-Out Mouse Project 
(KOMP) and obtained from the KOMP Repository (www.komp.org). Embryonic stem cells 
were generated from C57BL/6N mice and kept on the C57BL/6N background. Breeding of 
the cd93-deficient mice did not show a Mendelian ratio, with a very low ratio of homozygous 
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knockout mice observed. However, cd93 heterozygous (cd93+/-) mice had half the 
concentration of sCD93 in the periphery compared to their wild-type (cd93+/+) littermates 
(Supplemental Table 1), rendering this a relevant model to be used in comparisons to human 
studies, as humans have varying levels of sCD93 (11), rather than complete absence of 
sCD93. Therefore, this study focuses on cd93+/+ and cd93+/- animals. All mice were bred and 
kept at the Karolinska Institutet animal facility and with 12 hour day/night cycle with food 
and water ad libutim. All procedures were approved by the regional animal ethics authority.  
Characterization cd93-deficient mice 
Mouse scd93 was measured using MesoScale technology with antibodies directed against 
murine cd93 (capture antibody clone 223437, detection antibody BAF1696, R&D systems) 
using EDTA plasma from male mice (N=8 from each genotype) fed on western diet for 16 
weeks. Expression of cd93 on the B cell population (Online Supplemental Table 1) was 
determined by flow cytometry. Single cell suspensions of spleen cells from male mice (N=8 
from each genotype) fed on western diet for 16 weeks were used. Firstly, Fc receptors were 
blocked with anti-FcRII and III (clone 24.G2 in-house preparation). B cells were stained with 
anti-mouse CD45R eFlour450® (clone RA3-6B2 ebioscience) and anti-mouse-CD19 
conjugated with APC-Cy7 (clone 6D5 biolegend). The percent of IgG and IgM positive B 
cells was determined by using anti-mouse IgG conjugated with FITC (Biolegend Poly4060) 
and anti-mouse-IgM conjugated with APC (Biolegend RMM-1). Expression of cd93 on B 
cells was determined by anti-mouse cd93 conjugated with PE (Biolegend clone AA4.1) on 
Beckman Coulter Gallios™ flow cytometer. The percent of iNKT cells in the liver was 
determined using the previously published method (10) with the exception that a violet 
viability dye (Live/Dead Life technologies) was included, using the Beckman Coulter 
Gallios™ flow cytometer. 
10 
 
Tissue collection and assessment of atherosclerotic lesions in mice (apoe-/-cd93+/+ and apoe-/-
cd93+/-). 
For atherosclerosis studies, mice were crossed into apoe-deficient (apoe-/-) mice (originally 
from Jackson Laboratory) and backcrossed 6 generations to C57BL/6N. Homozygous for 
apoe deficiency mice, with 2 or 1 copies of the cd93 gene (apoe-/-cd93+/+ and apoe-/-cd93+/- 
respectively) were fed a normal rodent diet for 32 weeks, at which point blood was sampled 
via cardiac puncture. Plasma samples (EDTA) were stored at -80⁰C. Organs were perfused 
with sterile PBS and the descending thoracic aorta was collected into 4% paraformaldehyde. 
The thoracic aorta was pinned onto a paraffin bed and en face lipid content was determined by 
staining with Sudan IV (Sigma-Aldrich). Images were captured using a DC480 camera 
connected to a MZ6 stereomicroscope (both from Leica). Quantification of the area of all the 
plaques in a given aortic arch were summed and expressed as the percentage of the total 
surface area of the aorta using ImageJ software (NIH).  
Metabolic studies of mice (cd93+/+ and cd93+/-) 
For metabolic studies, cd93-deficient mice were fed a western diet (SDS custom diet: 21% fat 
0.2% cholesterol mixed in standard CRM (p) maintenance diet,) for 16 weeks. Glucose and 
insulin tolerance tests were conducted. After 4 hours of fasting, a bolus of glucose (1g/kg for 
glucose tolerance test) or insulin (0.75 U/kg for insulin tolerance test) was given by intra-
peritoneal injection. Blood was sampled from the tail vein at 15, 30, 60, 120 minutes.  
Pancreatic morphology in the cd93-deficient mouse model (cd93+/+ vs cd93+/-) 
Differences in pancreas morphology between genotypes were assessed by immuno-
histochemistry (IHC). Mice were fed a western diet for 16 weeks prior to removal of 
pancreas. Embedding and sectioning of the pancreas as well as rehydration and dehydration of 
sections were conducted as per standard protocols. Four pancreases were analysed per 
genotype. To assess presence and location of insulin, cd93 and von Willebrand Factor (vWF), 
11 
 
sections were boiled for 20 minutes in Diva Decloaker (Biocare Medical) and sections were 
treated with 3% hydrogen peroxidase before blocking in 5% goat serum in 1% bovine serum 
albumin. Serial sections were stained using antibodies against insulin (guinea pig anti-insulin, 
Abcam), vWF (rabbit anti-vWF, Abcam) and cd93 (rat anti-cd93, R&D). Of note, the anti-
cd93 antibody targets an extracellular epitope, thus is able to detect cell surface-attached, as 
well as soluble, cd93. After overnight incubation at 4⁰C, sections were incubated with 
biotinylated secondary antibodies (goat anti-guinea pig, Abcam; goat anti-rabbit; and rabbit 
anti-rat, Vector Laboratories respectively) for 1hr at room temperature. Peroxidase-
avidin/biotin complex was achieved using Vectastain ABC Elite kit (Vector Laboratories) and 
detected using Novo Red (Vector Laboratories) as per manufacturer’s directions and 
counterstained with haematoxylin. The numbers of islets were counted in parallel by 2 
researchers, using 3-5 haematoxylin and eosin-stained sections. The size of insulin-stained 
islets was measured using ImageJ software (NIH). The number of vWF-positive and total 
islets was counted and a percent of positive islet staining calculated (number vWF positive 
islets / total number islets and multiplied by 100). The pancreas from one cd93-/- mouse also 
fed on western diet for 16 weeks was included to confirm specificity of anti-cd93 staining. 
Blood vessel integrity (cd93+/+ vs cd93+/-) 
An in vivo blood vessel permeability assay was used by i.v. injection of 0.5% Evans blue into 
anesthetised 4 week old male mice. After 30min, mice were euthanized and perfused with 
PBS. After collection, the pancreases were treated with 50% trichloroacetic acid at a 1:4 ratio 
(ug/mL) and homogenised using Bio-Gen Pro200 (Pro Scientific) for 30 seconds. The amount 
of Evans blue was determined as previously published (24) and detected using GlowMax 
Multi with fluorescence 625/660-720 (Promega).  
 
Peripheral markers of endothelial damage (cd93+/+ vs cd93+/-) 
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Soluble E-selectin and vWF A2 were measured in the plasma of mice fed either a western diet 
of chow diet for 16 weeks. E-selectin was measured using Mesoscale and the DuoKit for E-
selectin (R&D Systems, Minneapolis, MN) with addition of SULFO-TAG labelled 
Streptavidin. vWF A2 was measured using SimpleStep Elisa kit from Abcam as per 
manufacturer’s directions. 
Statistical analysis of murine data 
Students T-Test was used to determine statistical significance between two groups, apart from 
when there was a need to determine significance between several groups then one-way 
ANOVA was used to establish significance with post-hoc analysis using Tukey’s multiple 
comparison test. When analysing repeated glucose metabolism measurements then a 2-way 
ANOVA repeated measurement test was used to establish significance with post-hoc analysis 
of Sidak’s multiple comparisons test all using PRISM (Graphpad Software, San Diego, USA). 
Analysis of sCD93 release from endothelial cells 
To assess the impact of diabetes-relevant conditions on sCD93 release, the human carotid 
endothelial cells (HCtAEC, in complete endothelial cell growth media (Cell Applications)) 
and human endothelial hybrid cell (EA.Hy 926, ATCC, in RPMI, 10% foetal calf serum and 
1% Penicillin and Streptomycin (Sigma-Aldrich)) were expanded in flasks coated with gelatin 
(Sigma-Aldrich). During passage 5, cells were seeded onto gelatin-coated 48 well plates. 
After overnight incubation with glucose-free DMEM (Sigma-Aldrich), HCtAEC were 
supplemented with 1% Heparin (Sigma-Aldrich), 0.5% endothelial cell growth supplement 
(Sigma-Aldrich) and both HCtAEC and EA.Hy were supplemented with 10% foetal bovine 
serum and 1% Penicillin and Streptomycin. Cells were then stimulated with or without 50nM 
Phorbol 12-myristate 13-acetate (PMA) or 50ug/mL lipopolysaccharide (LPS) in 5 or 30mM 
Glucose (Braun). sCD93 was measured as above.  
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Results 
Plasma levels of sCD93 in IMPROVE 
In IMPROVE, latitude was the strongest independent predictor of IMT (17). No significant 
association was observed between sCD93 and latitude (p=0.942). Consistent with previous 
reports (11), there was no significant difference between men and women (mean±sd: 
162±42ng/mL vs 163±45ng/mL, p=0.3833). Levels of sCD93 were significantly lower in 
subjects with type 2 diabetes (157±40ng/mL) compared to those without (164±45ng/mL, 
p<0.0001). Thus, the cohort was stratified for diabetes status as this is likely to impact upon 
further analysis of IMT or other CVD risk factors. 
sCD93 levels and metabolic or cardiovascular risk markers  
In the subjects without diabetes, sCD93 correlated with age, height, and metabolic markers 
(BMI, insulin, HOMA indices, vitamin D and adiponectin; Table 2). Consistent with lower 
levels being associated with poor metabolic control, sCD93 was positively correlated with 
adiponectin and vitamin D, but inversely with BMI, insulin and HOMA. The association 
between sCD93 and lipids was confounded by lipid-lowering medication (Table 2). In lipid-
lowering-naïve subjects, sCD93 levels were associated with an advantageous metabolic 
profile, i.e positively with HDL levels and negatively with TGs. A negative correlation was 
observed between sCD93 levels and SBP, however this association was lost when analysing 
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subjects without anti-hypertensive medication. Associations with metabolic variables 
remained significant after adjustment for age and sex (Online Supplemental Table 2). 
sCD93 levels and IMT in IMPROVE 
As cardiovascular risk factors have a large impact on IMT measures (16; 17), these 
parameters were considered for inclusion in multiple regression models. Proinsulin and 
insulin measurements were omitted as they are not informative in subjects with diabetes (due 
to influence of medication and pathology). Diabetes-stratified multiple regression analysis 
gave rise to 3 models: A) age and sex. B) with variables significant in both subjects with and 
without type 2 diabetes, where DBP, TGs, creatinine and current smoking were added to 
model A. C) further inclusion of variables significant in one stratum (LDL, IL5, adiponectin 
and SBP). sCD93 were not associated with any baseline or progression measures of IMT in 
subjects with or without type 2 diabetes, when adjusting for age and sex (Supplemental Table 
3), nor in the regression models adjusting for established CVD risk markers (data not shown). 
We could exclude lack of power as a reason for failing to detect an association (assuming an 
effect size of ≥0.009 gave power =0.99 for subjects without type 2 diabetes and 0.81 for the 
subjects with type 2 diabetes). Thus we conclude that sCD93 levels do not influence on IMT.  
Type 2 diabetes risk-associated SNPs and sCD93 levels 
A Mendelian randomisation experiment was conducted to assess whether reduced sCD93 
levels are a consequence or possible cause of type 2 diabetes. If reduced sCD93 levels are a 
consequence of diabetes-related processes and/or susceptibility, then genetic variants which 
influence risk of type 2 diabetes would be expected to influence sCD93 levels. Genotypes of 
53 (of 62 known (18)) type 2 diabetes risk-associated SNPs were available for the IMPROVE 
cohort and were analysed for association with sCD93 levels (adjusting for age, sex and 
population structure in subjects without diabetes). Individually, no SNP met the Bonferroni-
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corrected p value for significance (p<9.43E-4, Supplemental Table 4), nor was there any 
correlation with sCD93 levels for SNPs combined in an un-weighted SNP score (Spearmans 
rank rho=0.0045, p=0.8248). These findings indicate that genetic susceptibility to type 2 
diabetes is unlikely to be a cause of reduced CD93 levels; hence, it is possible that reduced 
sCD93 levels precede development of type 2 diabetes.  
Soluble CD93 levels in the prospective SDPP cohort 
In order to assess whether the multiple metabolic aberrations which characterize IMPROVE 
affect the results presented, the prospective SDPP cohort, specifically designed to assess 
potential biomarkers of type 2 diabetes, was investigated.  Baseline and follow-up features are 
presented in Supplemental Table 5 and Table 3, respectively. Baseline levels of sCD93 were 
lower in subjects with poor glucose regulation: NGT 163±44ng/mL, prediabetes 
158±44ng/mL and type 2 diabetes 158±41ng/mL (ANOVA p=0.23, adjustment for age and 
sex). Similarly, no significant difference was found between follow-up levels of NGT, pre-
diabetes or type 2 diabetes (153±42, 154±51 and 154±48 ng/mL, respectively). To assess 
whether baseline sCD93 levels influenced progression to prediabetes or to type 2 diabetes 
over the time, baseline levels were compared between subjects (all NGT at baseline) who 
were diagnosed as NGT, prediabetes or type 2 diabetes at follow-up. Subjects who remained 
NGT at follow-up had significantly higher baseline levels of sCD93 than those who 
progressed from NGT to type 2 diabetes during follow-up (166±44ng/mL vs 158±45ng/mL 
respectively, T-test p=0.016). A similar non-significant trend of higher baseline sCD93 levels 
was observed in subjects who remained NGT at follow-up compared to those who progressed 
to pre-diabetes during follow-up (166±44ng/mL vs 161±44ng/mL, respectively, p=0.058). 
Logistic regression demonstrated that baseline sCD93 levels were significantly associated 
with progression to poor metabolic control (prediabete or T2D, beta -0.612, se 0.272, 
p=0.024) but not T2D specifically (beta -0.573, se 0.346, p=0.098), and this was independent 
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of current smoking, blood pressure medication and BMI (beta -0.894, se 0.298, p=0.003). 
However, inclusion of sCD93 levels in the model did not provide additional benefits (area 
under ROC curve 0.73 irrespective of inclusion of sCD93). 
These results support the hypothesis that reduced sCD93 levels occur before onset of type 2 
diabetes.  
Cd93-deficient mouse model 
A cd93-deficient mouse model has previously been described (6), where there was no gross 
phenotypic abnormality. However, mice demonstrated reduced phagocytic activity (6), 
defective maturation of B cells and iNKT cells (23; 25) and altered vascular permeability in 
glioma (9). These mice lack only exon 1 of the cd93 gene and had a mixed genetic 
background, (129/sv embryonic stem cells crossed to C57BL/6J). In contrast, our strategy 
maintained a genetically pure strain, namely C57BL6/N, with the entire cd93 gene being 
deleted. This cd93-deficient mouse model again showed no gross phenotypic defect, however 
there was partial lethality. Importantly, mice carrying one cd93 gene (cd93+/-) had 
approximately half the concentration of circulating scd93 compared to wild type mice 
(cd93+/+, 104±18 vs 254±63 ng/mL respectively, p=0.008, Supplemental Table 1). Compared 
to cd93+/+, cd93+/- mice showed no difference in mature B cell populations (determined by 
percentage IgG or IgM positive B cells) or iNKT cells (Supplemental Table 1). Therefore, 
these mice were appropriate for our studies aimed at investigating whether reduced levels of 
scd93 influence development of atherosclerosis and type 2 diabetes. 
Atherosclerosis in apoe-/-cd93+/+ vs apoe-/-cd93+/- mice 
To investigate the impact of CD93 on atherosclerosis, the cd93-deficient mouse model was 
crossed with the apoe-deficient (apoe-/-) mice, commonly used to study atherosclerosis. Apoe-
/-cd93+/+ and apoe-/-cd93+/- mice were fed a chow diet until being sacrificed at 32 weeks. 
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Whilst atherosclerotic lesions were visible in the descending aorta, there was no difference 
between apoe-/-cd93+/+ and apoe-/-cd93+/- mice regarding the lesion area observed (Figure 1). 
Thus, these data are consistent with the human findings that scd93 levels do not influence 
IMT.  
Metabolic characteristics of cd93+/+ vs cd93+/ mice 
To mirror the human metabolic findings, we investigated whether mice with reduced sCD93 
levels had impaired glucose metabolism. When fed a chow diet, both genotypes demonstrated 
a similar rate of glucose clearance, however cd93+/- male mice had higher basal level of 
glucose compared with cd93+/+ (187.4 ± 13.6 mg/dL vs 161.9 ± 4.2 mg/dL respectively, after 
4 hour fasting, Figure 2. Female mice demonstrated no significant difference (137.5 ± 4.7 
mg/dL vs 137.4 ± 5.7 mg/dL, after 4 hour fasting, Online Supplement Figure 2). However, 
when fed a western diet (21% fat, 0.2% cholesterol), male cd93+/- mice demonstrated 
impaired clearance of glucose and reduced sensitivity to insulin compared to cd93+/+ mice, 
which was not due to a difference in weight (Figure 2). This was not seen in female mice 
(Online Supplement Figure 2). Levels of fasting insulin and biomarkers of metabolic 
dysregulation (leptin, glucagon, resistin and GLP-1) were measured and compared between 
cd93+/- and cd93+/+ mice (Table 4). Whilst not statistically different, a trend was observed 
whereby cd93+/- mice had increased levels of insulin and leptin levels compared to cd93+/+ 
mice and were more insulin resistant (as measured by HOMA-IR).  
Assessment of pancreas morphology (cd93+/+ vs cd93+/-) 
The number and the average size of islets did not differ between cd93+/+ and cd93+/- mice 
(21.7 vs 24.1, p=0.34 and 595 vs 622 pixels, p=0.42, respectively). Insulin staining was 
visible in islets in all genotypes, however some interstitial insulin staining was apparent in 
sections from the cd93+/- mice (Figure 3, top panel). As expected, vWF staining was restricted 
to endothelium in all genotypes (Figure 3, middle panel). In cd93+/+ mice, cd93 demonstrated 
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endothelial staining (as expected with cell surface-attached cd93; Figure 3, bottom panel) 
similar to that of vWF. Diffuse cd93 staining was also observed in the islets. Whilst this could 
reflect a previously unappreciated expression of cd93 by beta cells, we believe that it is more 
likely that the diffuse staining reflects the scd93 released from the endothelial cells. In cd93+/- 
mice, the endothelial cd93 staining was less obvious, but the diffuse cd93 staining was clearly 
visible. However, in the pancreas obtained from a cd93-/- mouse, no cd93 staining was 
observed. Interestingly, cd93+/- mice had a trend (p=0.08) of decreased percentage of vWF 
positive islets compared to cd93+/+ mice, indicating the presence of endothelial disturbances 
in western diet fed cd93+/- mice (Figure 4A). 
Pancreatic blood vessel integrity 
Given the role of cd93 in vessel leakage (9), and the interstitial insulin staining in cd93+/- 
mice, we performed an in vivo blood vessel permeability assay using Evans blue. Under 
physiologic conditions the endothelium is impermeable to albumin, so Evans blue-bound 
albumin remains confined within blood vessels. Presence of Evans blue within a tissue after 
perfusion with PBS indicates leakage out of blood vessels into the interstitial space. 
Interestingly, young cd93+/- mice had an increase in Evans blue compared to cd93+/+ 
littermates (Figure 4B). The finding that higher levels of Evans blue were detected in cd93+/- 
than cd93+/+ mice provided confirmation that the (albeit weak) interstitial insulin staining in 
the pancreas of cd93+/- mice was not merely an artifact. Thus, lacking cd93 even at a young 
age results in leaky vessels, however, neither young animals nor mice fed on rodent chow 
displayed a diabetes phenotype. Therefore, we questioned whether after metabolic stress of 
western diet there was signs of endothelial damage in plasma, indicated by soluble e-selectin 
and vWF A2. Indeed, cd93+/- mice fed on a western diet demonstrated an increase in both 
endothelial damage markers compared with cd93+/+ (Figure 4C and D), indicating endothelial 
damage in the western diet-fed cd93+/- mice.  
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Influence of high glucose levels on release of sCD93 from endothelial cells 
As diffuse cd93 staining was observed in islets and as metabolic regulation in mice was 
impaired after dietary stress, we investigated whether the release of sCD93 (by known 
stimuli) might be influenced by hyper-glycaemia, mimicking the prediabetes state. Glucose 
levels did not influence the release of sCD93 from primary HCtAEC under basal (media) or 
LPS-stimulated conditions (Online Supplemental Figure 3A), however hyper-glycaemia 
(30mM glucose) reduced PMA-stimulated release of sCD93 compared to normo-glycaemia 
(5mM glucose). This experiment was repeated with the EA.Hy 926 cell line, with comparable 
results (Online Supplemental Figure 3B). 
Discussion 
The main objective of this study was to elucidate whether sCD93 plays a role in metabolic or 
cardiovascular disease. Our results refute sCD93 as an important factor in the early vascular 
changes indicative of atherosclerosis, however they do provide solid evidence for a role of 
sCD93 in glucometabolic regulation and a starting point for understanding the role of CD93 
in these diseases. 
The most striking result from the present study is the finding that reduced levels of sCD93 
were associated with metabolic dysregulation. In addition, we show that: i) lower sCD93 
levels were observed in high CVD risk subjects with type 2 diabetes than those without; ii) 
insulin-related processes were associated with sCD93 levels in subjects without diabetes; iii) 
lower levels of sCD93 were not due to genetic susceptibility to type 2 diabetes; iv) lower 
sCD93 levels precede development of type 2 diabetes; v) dietary stress in a cd93-deficient 
mouse model caused impaired metabolic regulation and increased endothelial damage; vi) 
cd93 (both cell surface-bound and soluble) was detected in islets; vii) hyper-glycaemia 
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impaired the release of sCD93 by specific stimuli. The lack of association between sCD93 
levels and early atherosclerosis measures is consistent between human and mouse. 
Thus, we propose that CD93 expression and sCD93 release in pancreatic islets are 
components of stress responses and are important for endothelial integrity and thereby 
metabolic control. CD93-deficiency leads to leaky blood vessels, which under normal 
metabolic conditions is tolerated or compensated for. However, when stressed (inflammatory 
or metabolic), release of sCD93 is further impaired, possibly leading to endothelial damage. 
Leaky vessels and endothelial damage would permit insulin diffusion into the interstitial 
space leads to sub-optimal insulin delivery to distal tissues. These results are the first direct 
evidence for the recently proposed role for CD93 in type 2 diabetes (12).  
In view of previous publications on CD93, it should be noted that there was no evidence to 
suggest that changes in iNKT cells were responsible for the effects reported here, in contrast 
to previous reports (10). In addition, 2 SNPs associated with sCD93 levels in control subjects 
have been described (11). No associations were observed between these SNPs and sCD93 
levels or insulin sensitivity (Supplementary Table 6) in IMPROVE, nor do they demonstrate 
any association with type 2 diabetes (DIAGRAM consortium, n=100,589, rs2749812 
p=0.940, rs3746731 p=0.870 (26)). Whilst IMPROVE is the largest cohort to date with data 
on sCD93 levels, this cohort is not metabolically uniform, in contrast to the myocardial 
infarction cases and healthy controls (11), where few subjects were on lipid-lowering or anti-
hypertensive medication and very few subjects had type 2 diabetes. Therefore comparisons 
between the Mälarstig (11) and IMPROVE data should be approached with caution. We admit 
that the size of the SDPP replication study is limited, however, the use of OGTT to define 
glucose control categories and the length of follow-up compensate for the restricted sample 
size. A further caveat is that the murine model demonstrated a sex difference which was not 
seen in the clinical data. The murine studies were conducted in mice of reproductive age, thus 
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it is plausible that age-related differences in hormones might contribute to this discrepancy. 
Women of IMPROVE were all in post-menopausal, thus this effect was not seen. The SDPP 
cohort was younger so it cannot be assumed that female participants in SDPP are post-
menopausal, however the size of the cohort precluded assessment of sex-specific effects.  
Previously, release of sCD93, has been implicated as a response to stressors such as 
inflammatory, immune and angiogenic mediators.  Our demonstration of clear cd93 staining 
in pancreatic islets is novel and might reflect a protective function, whereby a deficiency in 
cd93 results in morphological and physiological changes in the pancreas. Furthermore, the in 
vitro studies showing that sCD93 was not released from endothelial cells as efficiently under 
hyper-glycaemia fits with the documented downward spiral of glycaemic control 
characteristic of type 2 diabetes progression. 
Differences in sCD93 levels between subjects with and without diabetes are subtle; therefore 
it is unlikely that measurement of sCD93 levels would have clinical utility as biomarker. 
However, given that this molecule might mediate both inflammatory and metabolic pathways, 
further investigation and understanding of CD93 functions is warranted and might provide 
opportunities for future preventative strategies. Having established the cd93-deficient mouse 
model and confirmed the human relevance, we are able to continue to conduct a deeper 
functional evaluation of cd93. 
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Table 1: IMPROVE cohort characteristics 
    without diabetes type 2 diabetes P 
N 
 
2470 901 
 Male  1138 (44.7) 533 (57.4) <0.0001 
Age (years) 64.2 (5.4) 64.2 (5.6) 0.8246 
Height (m) 1.67 (0.09) 1.69 (0.09) <0.0001 
BMI (kg/m2) 26.6 (3.9) 29.2 (4.6) <0.0001 
WHR 0.91 (0.08) 0.95 (0.09) <0.0001 
SBP 141 (19) 145 (18) <0.0001 
DBP 82 (10) 82 (10) 0.3524 
LDL (mmol/L) 3.71 (0.97) 3.07 (0.95) <0.0001 
HDL (mmol/L)* 1.31 (0.36) 1.14 (0.33) <0.0001 
Triglycerides (mmol/L)* 1.47 (0.90) 1.91 (1.82) <0.0001 
Fasting glucose (mmol/L)* 5.29 (0.67) 7.71 (2.18) <0.0001 
C reactive protein (mmol/L)* 2.89 (6.16) 3.20 (4.22) 0.0001 
CD93 (ng/mL)* 164 (45) 157 (40) <0.0001 
Fasting proinsulin (pmol/L)* 6.03 (6.26) 10.5 (8.88) <0.0001 
Fasting insulin (pmol/L)* 44.4 (61.5) 66.5 (88.4) <0.0001 
HOMA B* 68.9 (54.3) 50.8 (50.8) <0.0001 
HOMA IR* 0.83 (1.09) 1.33 (1.66) <0.0001 
Uric acid (mmol/L)* 309 (70) 333 (76) <0.0001 
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Creatinine (mmol/L)* 80.3 (17.7) 82.8 (17.7) <0.0001 
Vitamin D (nmol/L)* 50.7 (21.5) 48.2 (20.2) 0.963 
Adiponectin (ug/mL)* 14.2 (9.9) 9.43 (7.19) <0.0001 
Leptin (ng/mL)* 20.0 (17.0) 21.6 (17.4) 0.0138 
IL-5 (pg/mL)* 0.67 (1.82) 0.86 (3.50) <0.0001 
Pack years 9.84 (16.3) 14.1 (18.6) <0.0001 
Current smoking (%) 381 (15.0) 143 (15.4) 0.7483 
Lipid-lowering medication (%) 1268 (49.8) 449 (48.6) 0.542 
Anti-hypertensive medication (%) 1397 (54.8) 604 (65.0) <0.0001 
Ba
se
lin
e 
CC-IMTmean* 0.738 (0.141) 0.758 (0.145) 0.0001 
BIF-IMTmean* 1.131 (0.396) 1.190 (0.429) 0.0002 
IMTmean* 0.880 (0.196) 0.918 (0.206) <0.0001 
CC-IMTmax* 1.185 (0.196) 1.225 (0.412) 0.0035 
BIF-IMTmax* 1.840 (0.750) 1.954 (0.829) 0.0004 
IMTmax* 1.998 (0.792) 2.140 (0.862) <0.0001 
IMTmean-max* 1.239 (0.292) 1.290 (0.312) <0.0001 
Pr
og
re
ss
io
n 
CC-IMTmean 0.008 (0.025) 0.011 (0.034) 0.0031 
BIF-IMTmean 0.032 (0.070) 0.040 (0.087) 0.0134 
IMTmean 0.018 (0.030) 0.022 (0.035) 0.0007 
CC-IMTmax 0.013 (0.087) 0.019 (0.113) 0.1385 
BIF-IMTmax 0.047 (0.153) 0.058 (0.178) 0.0700 
IMTmax 0.040 (0.157) 0.056 (0.178) 0.0145 
IMTmean-max 0.162 (0.140) 0.188 (0.155) 0.0482 
fastest_progression 0.024 (0.051) 0.028 (0.054) <0.0001 
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Where: values are presented as mean (standard deviation) for continuous measures and n (%) for 
categorical measures. T2D was defined as diagnosis, anti-diabetic medication or fasting glucose 
>=7mmol/L; Vitamin D, adjusted for season of blood sampling; all IMT measured in mm. P for T-test. 
* log transformed prior to analysis. 
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Table 2: Spearmans rank correlation coefficients between sCD93 and cardiovascular risk 
markers 
  without diabetes type 2 diabetes 
  Rho P Rho P 
Sex -0.001 0.9671 -0.045 0.1882 
Age (years) 0.080 0.0001 0.166 <0.0001 
Height (m) -0.063 0.0022 -0.054 0.1163 
BMI (kg/m2) -0.073 0.0003 -0.042 0.2199 
WHR 0.023 0.2672 0.007 0.8511 
SBP (mmHg) -0.033 0.1067 -0.099 0.0042 
SBP (mmHg)* -0.023 0.4501 0.038 0.5048 
DBP (mmHg) -0.020 0.3319 -0.016 0.6428 
DBP (mmHg)* -0.050 0.0940 -0.003 0.9619 
LDL cholesterol (mmol/L) 0.042 0.0422 -0.028 0.4210 
LDL cholesterol (mmol/L)# 0.006 0.8265 0.048 0.3165 
HDL cholesterol (mmol/L) -0.073 0.0003 -0.081 0.0195 
HDL cholesterol (mmol/L)# 0.056 0.0343 -0.019 0.6872 
Triglycerides (mmol/L) -0.051 0.0131 -0.010 0.7663 
Triglycerides (mmol/L)# -0.098 0.0002 -0.074 0.1106 
Fasting glucose (mmol/L) -0.014 0.5101 0.020 0.5704 
C reactive protein (mmol/L) -0.014 0.5101 0.020 0.5704 
Current smoking 0.022 0.2833 -0.004 0.9027 
Lipid lowering medication -0.024 0.2455 0.000 0.9915 
Anti-hypertensive medication -0.025 0.2191 0.033 0.3467 
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fasting proinsulin (pmol/L) -0.025 0.2223 -0.024 0.4826 
fasting insulin (pmol/L) -0.078 0.0001 -0.007 0.8293 
HOMA B -0.054 0.0076 0.021 0.5333 
HOMA IR -0.080 0.0001 -0.011 0.7263 
Uric Acid (micromol/L) 0.019 0.3567 0.023 0.5073 
Creatinine (micromol/L) 0.173 <0.0001 0.237 <0.0001 
Vitamin D (nmol/L) 0.067 0.0009 0.032 0.3310 
Adiponectin (ug/mL) 0.063 0.0022 0.028 0.4159 
Leptin (ng/mL) -0.025 0.2197 0.000 0.9932 
IL-5 (pg/mL) 0.091 <0.0001 0.034 0.3060 
FRS 0.022 0.2719 0.103 0.0019 
Where: T2D was defined as diagnosis, anti-diabetic medication or fasting glucose 
>=7mmol/L;* subjects not on Anti-hypertensive medication (n= 1120 and 316 for subjects 
without diabetes and with type 2 diabetes respectively); # subjects not on lipid lowering 
medication (n= 1426 and 462 for subjects without diabetes and with type 2 diabetes 
respectively); FRS, Framingham risk score; Vitamin D, adjusted for season of blood 
sampling.  
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Table 3: Characteristics of the SDPP subjects diagnosed at baseline as NGT  
   Follow up diagnosis without diabetes prediabetes type 2 diabetes ANOVA p 
n* 370 314 158 
 male (%) 200 (54) 179 (57) 110 (69) 0.0019 
Ba
se
lin
e 
Age (years) 47.3 (4.7) 48.2 (4.4) 48.2 (4.6) 0.0102 
Height (m) 1.73 (0.09) 1.72 (0.09) 1.74 (0.09) 0.1294 
Weight (kg) 74.9 (12.4) 81.8 (14.1) 85.6 (15.2) <0.0001 
BMI (kg/m2) 24.9 (3.2) 27.6 (4.1) 28.4 (4.7) <0.0001 
WHR 0.84 (0.07) 0.87 (0.07) 0.90 (0.06) <0.0001 
SBP 121 (14) 128 (15) 130 (15) <0.0001 
DBP 76 (9) 80 (9) 81 (9) <0.0001 
Fasting glucose (mmol/L) 4.6 0 (0.49) 4.94 (0.50) 5.06 (0.56) <0.0001 
Fasting insulin (mU/L) 14.2 (6.3) 17.5 (9.0) 21.2 (10.2) <0.0001 
sCD93 (ng/mL) 166 (44) 161 (44) 158 (45) 0.0700 
Current smokers (%) 89 (22.2) 105 (29.2) 63 (36.8) 0.0012 
BP treatment (%) 19 (4.8) 38 (10.6) 18 (10.6) 0.0055 
Fo
llo
w
up
 
Follow-up time 9.1 (1.3) 9.2 (1.2) 9.5 (1.2) 0.0025 
Age (years) 56.5 (4.8) 57.4 (4.5) 57.7 (4.7) 0.0021 
Height (m) 1.72 (0.09) 1.71 (0.09) 1.73 (0.09) 0.0727 
Weight (kg) 77.1 (13.3) 86.5 (15.9) 91.0 (18.2) <0.0001 
BMI (kg/m2) 25.9 (3.4) 29.4 (4.8) 30.3 (5.8) <0.0001 
WHR 0.88 (0.06) 0.91 (0.06) 0.94 (0.07) <0.0001 
SBP 133 (17) 143 (17) 144 (18) <0.0001 
DBP 82 (10) 87 (10) 87 (11) <0.0001 
Fasting glucose (mmol/L) 4.86 (0.46) 5.72 (0.68) 7.35 (2.18) <0.0001 
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Fasting insulin (mU/L) 14.6 (6.0) 21.2 (11.9) 26.6 (13.2) <0.0001 
sCD93 (ng/mL) 153 (42) 154 (51) 154 (48) 0.9654 
delta sCD93 13 (46) 7 (52) 4 (55) 0.0814 
scurrent smokers (%) 61 (15.3) 73 (20.3) 34 (20.0) 0.1486 
T2D treatment (%) 0 0 39 (22.8) <0.0001 
BP treatment (%) 64 (16.0) 133 (36.9) 72 (42.1) <0.0001 
Where: values are presented as mean (standard deviation) for continuous measures  and n (%) for 
catagorical measures; Prediabetes defined as impaired glucose tolerance and/or impaired fasting 
glucose;* smallest n for any variable; delta sCD93, baseline sCD93 – follow-up sCD93. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Peripherial fasting levels of diabetes relevant analytes 
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cd93+/- cd93+/+ p-value 
Glucose (nmol/L) 12.6 11.1 0.03 
Insulin (ng/mL) 17.4 12.6 0.24 
Leptin (ng/mL) 62.2 51.5 0.24 
Resistin (ng/mL) 164 183 0.30 
Glucagon (ng/mL) 0.09 0.07 0.50 
GLP-1 (ng/mL) 0.03 0.01 0.26 
Homa-IR* 0.25 0.16 0.15 
Total cholesterol (mg/dL) 442 433 0.86 
Triglycerides (mg/dL) 138 139 0.89 
where: HOMA-IR* was calculated by G0 x I0 /22.5 where I0 is fasting blood insulin 
(μU/mL) and G0 fasting blood glucose (mmol/L) 
 
 
 
 
 
 
 
 
 
Figure legends 
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Figure 1:  Representative image of the descending aorta stained with sudan IV, from A) apoe-
/-cd93+/- and B) apoe-/-cd93+/+ mice. C) Quantification of lesions in the descending aorta of 
female and male apoe-/-cd93+/- (black dots, n=11 (6 male, 5 female)) or apoe-/-cd93+/+ (black 
squares, n=9 (5 male, 4 female)) mice .  
Figure 2: Glucose metabolism of cd93+/- male mice compared to cd93+/+ male mice (black 
dots and black squares respectively). A) Glucose tolerance test of cd93+/- and cd93+/+ male 
mice (n=10-13), aged 4 months, before given a western diet. B) Weight of cd93+/- and cd93+/+ 
male mice (n=9-12 respectively), after 16 weeks of western diet. C) Glucose tolerance test of 
cd93+/- and cd93+/+ male mice (n=9-12 respectively), after 16 weeks of western diet. D) 
Insulin tolerance test of cd93+/- and cd93+/+ male mice (n=9-11 respectively), after 16 weeks 
of western diet. Repeated measures 2 way ANOVA showed statistical significance for C and 
D with ** indicating p≤ 0.01 or * indicating p≤ 0.05 statistical significance at a particular 
time point/s between genotypes using post-hoc analysis of Sidak’s multiple comparisons test, 
error bar SEM. 
Figure 3: Immunohistochemistry of pancreas sections demonstrating the location of insulin, 
sCD93 and vWF in mice with 2, 1 or 0 copies of the cd93 gene (cd93+/+, cd93+/- and cd93-/- 
respectively). 
Figure 4: Vascular integrity and endothelial damage in cd93+/+ and cd93+/- mice. A) 
Percentage of vWF positive islets in pancreas from mice fed 16 weeks on western diet (4 of 
each genotype). B) Quantification of Evans blue in pancreas in cd93+/- and cd93+/+ mice (4 of 
each genotype, black and white bars respectively), * p≤ 0.05 Student’s T-test. C) Plasma 
levels of soluble vWF A2 in cd93+/- and cd93+/+ and mice and fed 16 weeks on western diet 
(black and white bars respectively) or on chow diet (dark and light hashed bars respectively), 
n=9-11 per genotype, * p≤ 0.05 one way ANOVA, using Tukey’s multiple comparison test 
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between genotypes and diet. D) Plasma levels of e-selectin in cd93+/- and cd93+/+ and mice 
and fed 16 weeks on western diet (black and white bars respectively) or on chow diet (dark 
and light hashed bars respectively), n=9-11 per genotype, * p≤ 0.05 Student’s T-test. All error 
bars indicate SEM.  
 
